Condition
Primary Myelofibrosis, Fibrotic Stage
Total Trials
5
Recruiting
2
Active
2
Completed
1
Success Rate
50.0%-37% vs avg
Key Insights
Highlights
Success Rate
50% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 85/100
Termination Rate
20.0%
1 terminated out of 5 trials
Success Rate
50.0%
-36.5% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 1 completed with results
Key Signals
50% success
Data Visualizations
Phase Distribution
4Total
Not Applicable (4)
Trial Status
Recruiting2
Terminated1
Completed1
Unknown1
Trial Success Rate
50.0%
Benchmark: 86.5%
Based on 1 completed trials
Clinical Trials (5)
Showing 5 of 5 trials
NCT04942080Not ApplicableRecruiting
Interest of CALR Allele Burden in Diagnosis and Follow-up of Patients With CALR Mutated Myeloproliferative Syndromes (CALRSUIVI)
NCT03869476Not ApplicableCompleted
Pilot Study for the Development of a Diagnostic Score to Differentiate Myeloproliferative Neoplasms.
NCT05882773Recruiting
Asian Myeloproliferative Neoplasm (MPN) Registry
NCT03116542Not ApplicableUnknown
18F-FLT (PET/CT) in Prefibrotic/Early Primary Myelofibrosis and Essential Thrombocythemia
NCT03121599Not ApplicableTerminated
18F-FLT (PET/CT) in Pediatrics With Myeloproliferative Neoplasms
Showing all 5 trials